Tag Archives: GlaxoSmithKline

New practical guide for businesses to measure air pollutant emissions across value chains

The Alliance for Clean Air, launched by the World Economic Forum and the Clean Air Fund, published a practical guide on how businesses can quantify the air pollutant emissions along their value chains The Alliance for Clean Air has adopted … Read the full press release

Nueva guía práctica para que las empresas midan las emisiones de contaminantes atmosféricos en las cadenas de valor

La Alianza para el Aire Limpio, lanzada por el Foro Económico Mundial y el Fondo de Aire Limpio, publicó una guía práctica sobre cómo las empresas pueden cuantificar las emisiones de contaminantes del aire a lo largo de sus cadenas … Read the full press release

GlaxoSmithKline: US FDA regulatory submission acceptance of New Drug Application for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor

(PRESS RELEASE) LONDON, 19-Apr-2022 — /EuropaWire/ — GlaxoSmithKline plc (LON: GSK), a British multinational science-led healthcare company, has announced the third major regulatory milestone for its daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the potential treatment of … Read the full press release

GlaxoSmithKline : acceptation de la soumission réglementaire de la FDA américaine pour la demande de nouveau médicament pour le daprodustat, un inhibiteur oral de la prolyl hydroxylase du facteur inductible par l’hypoxie

(COMMUNIQUÉ DE PRESSE) LONDRES, 19-Apr-2022 — /EuropaWire/ — GlaxoSmithKline plc (LON : GSK), une multinationale scientifique britannique , a annoncé la troisième étape réglementaire majeure pour son daprodustat, un inhibiteur oral du facteur prolyl hydroxylase inductible par l’hypoxie (HIF-PHI), pour le … Read the full press release

GlaxoSmithKline: Die Europäische Arzneimittel-Agentur (EMA) validierte den Antrag auf Marktzulassung (MAA) für Daprodustat, einen oralen Hypoxie-induzierbaren Faktor-Prolylhydroxylase-Hemmer zur Behandlung von Patienten mit Anämie bei chronischer Nierenerkrankung

Zulassungsantrag für die Behandlung von Anämie bei chronischer Nierenerkrankung basierend auf dem klinischen Phase-III-Studienprogramm ASCEND, bestehend aus fünf Studien, die alle ihre co-primären Wirksamkeits- und Sicherheitsendpunkte erreichten Die Zulassung der EMA-Anträge ist der erste große regulatorische Meilenstein für Daprodustat seit … Read the full press release

GlaxoSmithKline: European Medicines Agency (EMA) validated the marketing authorisation application (MAA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat patients with anaemia of chronic kidney disease

Submission for the treatment of anaemia of chronic kidney disease based on the ASCEND Phase III clinical trial programme, consisting of five trials that all met their co-primary efficacy and safety endpoints EMA file acceptance is the first major regulatory … Read the full press release

New Desiccant Products at Medica 2021

(PRESS RELEASE) BUCKINGHAMSHIRE, UK, 26-Oct-2021 — /EuropaWire/ — This year, Baltimore Innovations will be unveiling a new range of Humidity Balancing desiccants at Medica 2021. These HUMI-BALANCE™ Sachets are ideal for applications where products need to be protected not only … Read the full press release

Baltimore Innovations at U-Tech 2021

(PRESS RELEASE) BUCKINGHAMSHIRE, UK, 26-Oct-2021 — /EuropaWire/ — Moisture-control experts Baltimore Innovations have just announced their participation at U-Tech 2021 – the leading exhibition for the global polyurethane industry. The show will run from 16th until 18th November 2021, at … Read the full press release

Unilever to acquire the Health Food Drinks portfolio (GSK HFD) of GlaxoSmithKline (GSK) in Asia

LONDON/ ROTTERDAM, 04-Dec-2018 — /EuropaWire/ — Unilever today announced it has signed an agreement to acquire the Health Food Drinks portfolio (GSK HFD) of GlaxoSmithKline (GSK) in India, Bangladesh and 20 other predominantly Asian markets. The transaction consists of three elements: … Read the full press release

GlaxoSmithKline to present comprehensive portfolio of respiratory research and scientific innovation at the American Thoracic Society (ATS) conference

Brentford, United Kingdom, 17-May-2018 — /EuropaWire/ — GlaxoSmithKline plc (GSK) will present extensive data from across its respiratory portfolio, pipeline and early phase research programmes at the American Thoracic Society (ATS) conference in San Diego, USA, 19-23 May 2018. Data presented … Read the full press release

GlaxoSmithKline, Innoviva: Landmark IMPACT study shows significant benefits of Trelegy Ellipta for patients with chronic obstructive pulmonary disease (COPD)

LONDON, 20-Apr-2018 — /EuropaWire/ — Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life. GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the … Read the full press release

Relieve the Stress from Asthma Management with New MyAsthma App

NOTTINGHAM, 18-Apr-2017 — /EuropaWire/ — A new and unique smartphone app to help people with asthma manage their condition has been developed by lung experts at the Nottingham Respiratory Research Unit and the pharmaceutical company GlaxoSmithKline (GSK). The MyAsthma app has been launched … Read the full press release

GlaxoSmithKline welcomes Brian McNamara as CEO of GSK’s Consumer Healthcare division

LONDON, 29-Sep-2016 — /EuropaWire/ — GSK today announced that Brian McNamara, is appointed Chief Executive Officer (CEO) of GSK’s Consumer Healthcare division effective immediately. He succeeds Emma Walmsley who was last week appointed GSK CEO Designate succeeding Sir Andrew Witty as … Read the full press release

GlaxoSmithKline completes sale of remaining stake in Aspen Pharmacare Holdings Ltd at ZAR 300 per share

LONDON, 29-Sep-2016 — /EuropaWire/ — Further to the announcement by GlaxoSmithKline on 28 September 2016, GlaxoSmithKline has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings Ltd (“Aspen”) at a price of ZAR 300 per share (the … Read the full press release

GlaxoSmithKline intends to sell remaining stake in Aspen Pharmacare Holdings Ltd

LONDON, 29-Sep-2016 — /EuropaWire/ — GlaxoSmithKline announces that it intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd (“Aspen”). The disposal will be through a placing of ordinary shares in Aspen to institutional investors (the “Offering”). The Offering is … Read the full press release

Kuehne + Nagel to run the core business of transporting products from the raw materials supplier to trade customers for GlaxoSmithKline (GSK)

London / UK, Schindellegi / CH, 13-1-2016 — /EuropaWire/ — Kuehne + Nagel and GSK signed an end-to-end global logistics partnership until 2021 that will see Kuehne + Nagel run the core business of transporting products from the raw materials … Read the full press release

Urs Rohner to join GlaxoSmithKline’s Board as Non-Executive Director from 1 January 2015

LONDON, 9-10-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE: GSK) today announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective 1 January 2015. On appointment, Mr Rohner will also become a member of GSK’s Remuneration … Read the full press release

GlaxoSmithKline and Medicines for Malaria Venture start phase III global programme of tafenoquine for the treatment of Plasmodium vivax malaria

London, 29-4-2014 — /EuropaWire/ — GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) today announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine, an investigational medicine which is being developed for the treatment and … Read the full press release

GlaxoSmithKline’s Incruse® (umeclidinium) gets European Commission marketing authorisation as maintenance bronchodilator treatment of COPD

London, 29-4-2014 — /EuropaWire/ — GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse® (umeclidinium) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Now licensed across … Read the full press release

GlaxoSmithKline delivers Q3 core EPS of 28.9p (+16% CER) and dividend of 19p (+6%)

London, UK, 23-10-2013 — /EuropaWire/ — GSK announces Q3 core EPS growth of 16% and dividend of 19p Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies Pharma & Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by … Read the full press release

GlaxoSmithKline submitted NDA to US FDA for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler

London, UK, 23-10-2013 — /EuropaWire/ — GlaxoSmithKline plc (LSE:GSK) today announced the submission of a New Drug Application (NDA) in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler. The NDA … Read the full press release

GSK and Pfizer owned ViiV Healthcare announced US regulatory submission for STR combining dolutegravir with abacavir and lamivudine for people living with HIV

London, UK, 23-10-2013 — /EuropaWire/ — ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lamivudine for the treatment of people living with HIV-1. This New Drug … Read the full press release